{
    "clinical_study": {
        "@rank": "18394", 
        "acronym": "NUTREND", 
        "arm_group": [
            {
                "arm_group_label": "lipids", 
                "arm_group_type": "Experimental", 
                "description": "The study will be randomized (on the order of taking the products: a single dose of lipids or a single dose of flavonoids), single-blinded, cross-over for each population (healthy and metabolic syndrome)."
            }, 
            {
                "arm_group_label": "flavonoids", 
                "arm_group_type": "Other", 
                "description": "The study will be randomized (on the order of taking the products: a single dose of lipids or a single dose of flavonoids), single-blinded, cross-over for each population (healthy and metabolic syndrome)."
            }
        ], 
        "brief_summary": {
            "textblock": "The main objective is to develop and validate new endothelial function markers\n      discriminating and reproducible by assessing the ability to reveal changes in endothelial\n      function in response to positive and negative nutritional stimuli."
        }, 
        "brief_title": "Development of Endothelial Biomarkers", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Metabolic Syndrome", 
        "condition_browse": {
            "mesh_term": "Metabolic Syndrome X"
        }, 
        "detailed_description": {
            "textblock": "The study will be randomized (on the order of taking the products: a single dose of lipids\n      or a single dose of flavonoids), single-blinded, cross-over for each population (healthy and\n      metabolic syndrome)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  - 40 to 65 years old\n\n          -  male\n\n          -  non-smokers\n\n        Specific inclusion criteria for healthy subjects :\n\n          -  Healthy subjects should not take antihypertensive or statin.\n\n          -  Healthy subjects should not present metabolic syndrome but one criterion of the\n             metabolic syndrome will be tolerated.\n\n        Specific inclusion criteria for subjects with metabolic syndrome :\n\n        - subjects with metabolic syndrome must have at least 3 of the 5 criteria associated with\n        the metabolic syndrome.\n\n        Exclusion Criteria:\n\n          -  treatment vasodilator nitric oxide liberating,\n\n          -  diabetes and coronary artery disease,\n\n          -  chronic alcoholism,\n\n          -  severe hepatic impairment,\n\n          -  end stage renal failure or dialysis,\n\n          -  neurological tremor,\n\n          -  cancer, mental illness or other severe disease which can impact informed consent and\n             / or results,\n\n          -  Refusal to be registered in the National File of Volunteers\n\n          -  Person in exclusion of the National Volunteer File"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 24, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02006810", 
            "org_study_id": "CHU-0168", 
            "secondary_id": "2013-A00205-40"
        }, 
        "intervention": {
            "arm_group_label": [
                "lipids", 
                "flavonoids"
            ], 
            "intervention_name": "Induction of endothelial function variations", 
            "intervention_type": "Behavioral", 
            "other_name": [
                "Improvement with cocoa polyphenol dose", 
                "Induction of dysfunction with lipid dose"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Endothelium biomarkers", 
            "Atherosclerotic disease", 
            "Endothelial function", 
            "Nutritional stimuli"
        ], 
        "lastchanged_date": "December 5, 2013", 
        "location": {
            "contact": {
                "email": "placarin@chu-clermontferrand.fr", 
                "last_name": "Patrick LACARIN", 
                "phone": "04 73 75 11 95"
            }, 
            "facility": {
                "address": {
                    "city": "Clermont-Ferrand", 
                    "country": "France", 
                    "zip": "63003"
                }, 
                "name": "CHU de Clermont-Ferrand"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "2", 
        "official_title": "Development of Endothelial Biomarkers for Use in Cohort Studies. Comparison With Reference Biomarkers.", 
        "overall_contact": {
            "email": "placarin@chu-clermontferrand.fr", 
            "last_name": "Patrick LACARIN", 
            "phone": "04 73 75 11 95"
        }, 
        "overall_official": {
            "affiliation": "University Hospital, Clermont-Ferrand", 
            "last_name": "Nicolas BARBER CHAMOUX", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Ministry of Health"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Changes in endothelial function from baseline at 150 mn after the product intake, evaluated by:\n- Flow Mediated Dilatation (FMD) (reference)\nCompared to:\nHyperemic Velocity Time Integral (VTI)\nEndothelial microparticles (MPE)", 
            "measure": "Flow Mediated Dilatation (FMD)compared to hyperemic velocity time integral (VTI) and endothelial microparticles (MPE)", 
            "safety_issue": "Yes", 
            "time_frame": "at  150 mn after the product intake"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02006810"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Changes in endothelial function from baseline at 150 mn after the product intake, evaluated by:\nCell Adhesion Molecule (CAM)\nMicro-RNA (miRNA)", 
            "measure": "Changes in endothelial function evaluated by cell adhesion molecule (CAM) and micro-RNA (miRNA)", 
            "safety_issue": "Yes", 
            "time_frame": "at 150 mn after the product intake"
        }, 
        "source": "University Hospital, Clermont-Ferrand", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University Hospital, Clermont-Ferrand", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}